NCT00002248CompletedPhase 1
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Trial of the Efficacy and Safety of Bovine Anti-Cryptosporidium Immunoglobulin (BACI) in the Treatment of Cryptosporidium Enteritis in AIDS Patients
Univax Biologics Inc11 sites in 1 country40 target enrollmentStarted: August 31, 2001Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 40
- Locations
- 11
Study Overview
Brief Summary
PRIMARY: To assess the effect of bovine anti-Cryptosporidium immunoglobulin (BACI) on the volume of diarrhea due to Cryptosporidium parvum in AIDS patients who have protracted Cryptosporidium enteritis.
SECONDARY: To assess changes in stool consistency and frequency, body weight, and safety in this patient population.
Detailed Description
Forty patients are randomized to receive either BACI or placebo (bovine colostrum from non-immunized cattle) for 1 week. The double-blind portion of the study will be followed by an open-label phase in which all 40 patients receive BACI for 1 week.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Concurrent Medication:
- •Antidiarrheal compounds (if dose remains stable).
- •Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV therapy (provided dose was stable for at least 4 weeks prior to study entry).
- •Patients must have:
- •Cryptosporidium parvum enteritis.
- •Chronic diarrhea.
- •Life expectancy of at least 4 weeks.
- •Ability to tolerate food by mouth.
- •Ability to take the histamine H2-receptor antagonist famotidine (Pepcid).
- •Prior Medication:
- •Antidiarrheal compounds (provided dose has remained stable in the 7 days prior to study entry).
- •Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC), or alternative HIV therapy (provided dose has remained stable for at least 4 weeks prior to study entry).
Exclusion Criteria
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Concurrent unresolved clinical infections with enteric pathogens other than C. parvum (e.g., rotavirus, Salmonella, Shigella, Campylobacter, Giardia, C. difficile toxin, Yersinia, amebiasis, MAI, CMV, Microsporida) as determined by history or routine microbiology screening.
- •Other acute infections or concurrent immediately life-threatening medical crisis other than cryptosporidiosis.
- •Grossly bloody diarrhea.
- •Known allergy to milk or milk products (other than lactose intolerance).
- •Prior Medication:
- •Other experimental therapy (e.g., macrolide antibiotics, paromomycin) within 30 days prior to study entry.
Investigators
Study Sites (11)
Loading locations...
Similar Trials
Terminated
Not Applicable
To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC PatientsClostridium DifficileNCT02730325Northwestern University10
Completed
Not Applicable
A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy VolunteersTBNCT00480714University of Oxford10
Completed
Phase 2
A Pilot Study of the Effects of BCG Immunization on CSF and Blood-based Biomarkers in Older Adults.HealthyNCT04507126Massachusetts General Hospital20
Completed
Phase 1
A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy VolunteersTBNCT00480688University of Oxford11
Completed
Phase 2
The Effect of Colostrum Bovinum Supplementation in Endurance AthletesSports NutritionBiochemical MarkersExercise PerformanceAerobic CapacitySupplementationNCT06390670Poznan University of Physical Education58